Here, we discover that the European Medicines Agency works to foster scientific excellence in the evaluation and supervision of medicines for the benefit of public and animal health in the European Union.
Here, we focus on some of the key issues facing the pharmaceutical industry throughout Europe.
In this article, Dr Gerry Morrow shares his thoughts on the medical use of cannabinoids and marijuana.
Here, we discover the World Health Organization perspective on cannabidiol (CBD), including how there has been a shift in how CBD is socially perceived following reports and recommendations.
Investment Manager at the Ministry of Foreign Affairs of Denmark, Michael Prytz, charts the rapid development of the medical cannabis market in Europe and provides a look at the Danish model in this vein.
Vatra Syla, Head of Marketing, Storz & Bickel GmbH & Co. KG, discusses the importance of medical cannabis vaporizers.
Here, we have a brief look at the different methods of using CBD, and how each method affects bioavailability.
John Binns, Partner at BCL Solicitors LLP looks at the UK’s cannabis laws and how they could be improved.
Laura Clews, Managing Associate at IP attorneys Mathys & Squire, analyses the protection for innovative new products in the medical cannabis & CBD sector.
Dr Nikos Xynos, PhD in Pharmaceutical Sciences/Natural Products Chemistry and MD a Nomad Labs, explores the various pathways to cannabinoid extraction, refining and purification technologies.
Rebekah Shaman, Managing Director at British Hemp Alliance takes a close look at the future of the British hemp industry in this article.
Spectrum Therapeutics UK lifts the lid here on a pilot analysis of medicinal cannabis use that will run in Denmark until January 2022.
Following the first two articles that discussed the treatment of cancer and pain, this third piece will focus on the use of cannabinoids to treat psoriasis and rheumatoid arthritis.
Joe Seaman, Head of Client Relations at Naturalis London, tells us how the firm is providing quality CBD, trusted education and tailored consumer advice.
Dr. Frank D'Ambrosio, CMO of Block Commodities Plc, provides an insight into the UK’s medical cannabis industry.
Katharina Zedlacher, PR and communications at BioBloom GmbH, details the recent studies conducted to highlight how cannabinoid CBDa (cannabidiolic acid) increases bioavailability of CBD and its health-promoting properties.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health (NIH), shares his thoughts on closing gaps in cannabinoid research to make progress in pain management.
Dr Shiksha Gallow, Medical Director of Biodata and Head Researcher at Cannabis Oil Research, provides evidence-based research on cannabinoids for treating MS and Prostate Cancer.
Gregory Land, CEO at Canna CBD Limited, highlights the dangers of purchasing cannabidiol (CBD) from an unreputable source.
John Wallace, Managing Director at Mile High Labs International, Ltd. explores the market of CBD in food and beverages, including regulation.